EDIT

Business Context and Reporting Period

Editas Medicine, Inc. (EDIT) is a pioneering gene editing company focused on developing genomic medicines. This Form 10-Q covers the quarterly period ended September 30, 2025. The company operates as a single segment and has not yet generated product revenue, relying on equity financings, collaboration payments (notably with Bristol-Myers Squibb and Vertex Pharmaceuticals), and the sale of future revenues to fund operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Q3 2025 revenue increased significantly to $7.5 million from $0.1 million in Q3 2024, driven by a milestone achievement under the collaboration with Bristol-Myers Squibb (BMS).
• Expense Reduction: Operating expenses decreased by 51% in Q3 2025 compared to Q3 2024. Research and Development (R&D) expenses dropped 58% to $19.8 million, and General and Administrative (G&A) expenses fell 32% to $12.3 million. These reductions are primarily due to the discontinuation of the reni-cel program and a workforce reduction of approximately 65% (180 positions) approved in December 2024.
• Restructuring Charges: While no restructuring charges were recorded in Q3 2025, the nine-month period included $66.9 million in restructuring and impairment charges. This included $52.3 million in contract termination costs, $4.3 million in employee termination benefits, and $3.7 million in asset impairments related to the reni-cel program wind-down.
• Net Loss Improvement: The net loss narrowed by 60% in Q3 2025 compared to the prior year, reflecting the significant cost-cutting measures.

Guidance, Outlook, and Risks

• Strategic Focus: The company is pivoting resources toward its lead in vivo candidate, EDIT-401, targeting LDL-cholesterol reduction. Preclinical data in non-human primates showed LDL-C reductions exceeding 90%. The company plans to submit an Investigational New Drug (IND) application by mid-2026.
• Liquidity Outlook: As of November 10, 2025, management expects existing cash and equivalents to fund operations into the third quarter of 2027. The company maintains an At-The-Market (ATM) facility with $123.6 million remaining available for issuance as of September 30, 2025.
• Key Risks:
  • Intellectual Property: Ongoing patent interference proceedings involving CRISPR/Cas9 technology with third parties (e.g., CVC, ToolGen, Sigma-Aldrich) and the Broad Institute/Harvard. Recent court decisions have remanded some proceedings for further review, creating uncertainty regarding patent validity.
  • Capital Needs: The company has never been profitable and expects to incur significant losses for the foreseeable future. Failure to secure additional financing could force delays in development.
  • Development Risk: High risk of failure in preclinical studies and clinical trials for EDIT-401 and other candidates.

Investor Verification Checklist

• Verify the timeline and regulatory status of the EDIT-401 IND submission planned for mid-2026.
• Monitor the status of patent interference proceedings with the USPTO and Federal Circuit, as outcomes could impact the company's core IP portfolio.
• Track the utilization of the ATM facility and the timing of future equity raises to ensure the cash runway extends through 2027.
• Review the Vertex Pharmaceuticals license agreement terms, specifically the timing of future annual license fees and the contingent upfront payment, which are key revenue drivers.
• Assess the completion of the reni-cel program wind-down and the associated remaining restructuring liabilities.